Research Studies Finder

Use of elexacaftor-texacaftor-ivacaftor ("ETI"), also known as Trikafta, is associated with weight gain in most people with cystic fibrosis (CF) who take this medication. However, some people gain more or less weight than is expected, and this can be either beneficial or problematic based on the individual's starting weight. The goal of this study is to compare factors between children and young adults with CF who have either had robust or minimal weight gain after one year of treatment with ETI.This observational study requires one study visit to CHOP that will last approximately 6 hours.

The purpose of this study to learn more about the brain function of females with Rett Syndrome and how it compares to the brain function of typically developing females. The primary investigator of the study is Dr. Eric Marsh. For our research to be successful we need to partner with families who have a typically developing daughter between the age of 1 and 17. If your child agrees to help us with our study she will be asked to:

• Complete intelligence testing
• Receive an Evoked Potential measurement - this is a non-invasive procedure similar to an EEG.
• Complete yearly follow up visits

A study to investigate changes of symptoms and esophageal cell structure with tezepelumab compared with placebo in patients aged 12 to 80 years old with eosinophilic esophagitis. Subjects up to 21 years of age will be enrolled at CHOP.

The purpose of this study is to find out if myofascial release therapy (MFR), (a massage method that will be used in the belly area), will improve the symptoms in CHOP patients with Irritable Bowel Syndrome (IBS). Participation will last approximately 8 months which includes in person visits and remote follow-up (surveys only). The MFR intervention is comprised of 6 once a week in-person visits that will be conducted by a licensed massage therapist. This therapist will train participants in order for them to self-administer MFR therapy at home, daily. Participants will be asked to record their IBS symptoms throughout their study participation.

The Childrens Hospital of Philadelphia is seekinghealthy adolescents between the ages of 12-13, who are currently in the 7^thgrade,to participate in the Sleep and Growth Study 2. The purpose of this research is to learn more about the changes in sleep and body size in adolescents as they transition from middle to high school. Participants will be asked to visit CHOP so that we can measure their bone density. Following this visit, participants will wear a sleep tracker over a 2-week period and speak to a team member by phone on three occasions about the types of food eaten in the previous 24 hours. If you and your child agree to participate, the study will involve 3 visits over approximately 2 years. All participants are compensated for their time and effort.For more information and study details, please call 215-590-2383, ext. 1, or emails_grow@chop.edu.

The purpose of this investigation is to evaluate the impact of non-persistent and persistent chemical exposures on autoimmunity, gene expression and the microbiome in children with and without Crohns disease. If these chemical exposures are associated with differences in the epigenome and microbiome that are known to predispose for Crohns disease, the proposed research could further support changes in dietary behaviors to limit exposure, and efforts to regulate manufacturing processes that unintentionally and intentionally add these chemicals to food.

The purpose of this study is to compare the genes of African American children and adults who have inflammatory bowel disease (IBD) with the genes of those who do not have IBD. Genes are pieces of hereditary material found in human cells. How an individual's genes cause intestinal inflammation in IBD is still being tested and not much is known about the association between genes and IBD in individuals with African ancestry. We hope to understand which genes cause IBD and if certain genes can help doctors personalize treatment for patients with IBD. For more information please contact IBDResearch@email.chop.edu.

This study was designed to measure components or metabolites of PEG 3350 in blood and urine from children who were already taking PEG 3350 and to compare these levels to measurements of the same molecules from a group of children who were not taking PEG 3350. PEG 3350 was not prescribed as part of this study. Participants completed questionnaires and provided access to their medical records.Enrollment for this study has been completed. Laboratory analysis of specimens and data analysis are being conducted. This work will be submitted for publication once all analyses have been completed. When available, study results will be accessible on https://classic.clinicaltrials.gov/ct2/show/NCT05424757.

The purpose of this study is to characterize the microbiome in children with Crohns disease who have perianal fistula and to compare it to other children with Crohns disease who do not have perianal disease. Studying the role of the microbiome in perianal fistula may help us to develop new therapies.

The purpose of this study is to evaluate how safe and effective the drug Qsymia (Phentermine/Topiramate of Ph/T) is for children, adolescents, and young adults with hypothalamic obesity. We will also evaluate if Ph/T helps with weight loss and changes in hunger in patients with hypothalamic obesity.

If you are determined to be eligible, then your participation will last for approximately 8 months. Participants will be asked to complete up to 5 in-person visits and 5 telephone safety check-ins. During the study you will be randomly assigned to study drug (phentermine/topiramate) or placebo for 28 weeks.

You will complete study procedures including blood tests, ECGs, mobile cardiac outpatient telemetry, body composition scan, and questionnaires. Compensation and reimbursement of limited travel expenses is available.